Ahn Sung Soo, Han Minkyung, Jung Inkyung, Kim Chi Young
Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea.
Biostatistics Collaboration Unit, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea.
Rheumatology (Oxford). 2025 Jul 1;64(7):4181-4189. doi: 10.1093/rheumatology/keaf135.
Recent studies have raised concerns regarding usage of opioids, a class of drugs widely used for managing chronic pain in musculoskeletal disorders; however, its potential risks remain incompletely understood. This study aimed to evaluate the association between oral opioid use and mortality in a nationwide inflammatory arthritides (IA) cohort.
Data were obtained from the National Health Insurance Sharing Service database in South Korea, including 161 907 patients with seropositive RA, AS and PsA between 2010 and 2022. Patient demographics, laboratory variables and medication use were recorded. Mortality risk associated with oral opioid use was evaluated using time-dependent Cox proportional hazards models, and a 6-month lagged analysis was conducted to consider the delayed effects of oral opioid exposure on mortality.
Oral opioid use was associated with increased patient mortality (hazard ratio [HR] 1.60, 95% confidence interval [CI] 1.11-2.32, P = 0.012), with this association remaining significant even in the 6-month lag-adjusted model (HR 1.71, 95% CI 1.15-2.54, P = 0.008). The annual prescription rate of oral opioids increased steadily during the study period, reaching 47.5% by 2022. In subgroup analyses, male patients had significantly higher mortality risk associated with oral opioid use, whereas this risk was not evident among female patients.
Oral opioids, prescribed to a substantial proportion of patients with IA, were associated with higher mortality, particularly among male patients. These findings emphasize that cautious opioid prescription is required in this population, and seeking alternative pain management approaches may be warranted to improve patient outcomes.
近期研究引发了对阿片类药物使用的关注,这类药物广泛用于管理肌肉骨骼疾病中的慢性疼痛;然而,其潜在风险仍未被完全理解。本研究旨在评估在全国性炎症性关节炎(IA)队列中口服阿片类药物使用与死亡率之间的关联。
数据取自韩国国民健康保险共享服务数据库,包括2010年至2022年间161907例血清阳性类风湿关节炎、强直性脊柱炎和银屑病关节炎患者。记录患者人口统计学信息、实验室变量和用药情况。使用时间依赖性Cox比例风险模型评估口服阿片类药物使用相关的死亡风险,并进行6个月滞后分析以考虑口服阿片类药物暴露对死亡率的延迟影响。
口服阿片类药物使用与患者死亡率增加相关(风险比[HR] 1.60,95%置信区间[CI] 1.11 - 2.32,P = 0.012),即使在6个月滞后调整模型中这种关联仍显著(HR 1.71,95% CI 1.15 - 2.54,P = 0.008)。在研究期间口服阿片类药物的年处方率稳步上升,到2022年达到47.5%。在亚组分析中,男性患者口服阿片类药物使用相关的死亡风险显著更高,而女性患者中这种风险不明显。
相当比例的IA患者使用的口服阿片类药物与较高死亡率相关,尤其是男性患者。这些发现强调在该人群中需要谨慎开具阿片类药物处方,并且可能有必要寻求替代的疼痛管理方法以改善患者预后。